Mechanism of Ocrelizumab in B-Cell Depletion

How does ocrelizumab target CD20-positive B cells to drive B-cell depletion?

Ocrelizumab binds to CD20 on B cells and drives their depletion primarily through antibody-dependent cellular cytotoxicity mediated by monocytes via Fcγ receptor pathways, achieving rapid and sustained reduction of circulating B cells while also depleting CD20-positive T-cell subsets.

Abstract

Ocrelizumab is a humanized anti-CD20 monoclonal antibody that targets the same CD20 epitope as rituximab but achieves B-cell depletion primarily through antibody-dependent cellular cytotoxicity (ADCC) rather than complement-dependent cytotoxicity (CDC). The antibody was engineered with amino acid modifications to enhance binding to Fcγ receptor IIIa, resulting in two- to five-fold greater ADCC activity compared to rituximab. Monocytes serve as the dominant effector cells mediating B-cell depletion through FcγRI and FcγRIII-dependent pathways, achieving rapid onset within hours and near-complete depletion (>95%) of circulating B cells by week 2. However, depletion efficiency varies across anatomical compartments, with secondary lymphoid organs retaining resistant B-cell subpopulations and bone marrow showing the weakest reduction. Ocrelizumab also co-depletes CD20-positive T-cell subsets and novel dual-expressor lymphocytes expressing both T-cell and B-cell receptors.

B-cell recovery begins in bone marrow and spleen before appearing in blood, with median time to repletion of 72 weeks. The phenotype of reconstituting B cells varies by immunological context: in settings with ongoing antigen stimulation, recovery is characterized by expansion of differentiated, myelin-reactive B cells, whereas absence of stimulation favors naive B-cell reconstitution. Treatment induces secondary immunological changes including increased BAFF levels and decreased sTACI, which may enhance regulatory plasma cell development and contribute to therapeutic efficacy. The ADCC-predominant mechanism provides more sustained depletion than CDC-predominant antibodies while potentially offering better tolerability.

Results

Characteristics of Included Studies

Mechanisms of CD20 Targeting and B-cell Depletion

CD20 Binding Characteristics

Ocrelizumab is a humanized anti-CD20 monoclonal antibody that binds to the same epitope on the large extracellular loop of CD20 as rituximab. The antibody is classified as a type I anti-CD20 agent capable of crosslinking CD20 tetramers. Enhanced binding to low-affinity variants of Fcγ receptor IIIa distinguishes ocrelizumab from rituximab, contributing to its enhanced effector function. The antibody was specifically engineered through amino acid modifications in its Fc region to increase antibody-dependent cellular cytotoxicity (ADCC) activity.

Cytotoxic Mechanisms

Ocrelizumab depletes B cells through multiple cytotoxic pathways, with ADCC as the primary mechanism. The antibody exhibits two- to five-fold greater ADCC activity compared to rituximab, while demonstrating three- to five-fold lower complement-dependent cytotoxicity (CDC) activity. Both ocrelizumab and ofatumumab can induce ADCC and CDC, though ofatumumab demonstrates stronger CDC effects, particularly at low CD20 expression levels. Studies in mouse models demonstrated that B-cell depletion is completely dependent on effector cell Fc receptor expression, with monocytes serving as the dominant effector cells.

Patterns of B-cell Depletion

B-cell Subpopulations

Ocrelizumab targets CD20-positive B cells, resulting in significant reductions across multiple B-cell subsets including naive B cells, memory B cells, transitional B cells, and plasmablasts. Plasma cells, which lack CD20 expression, remain resistant to depletion, as do CD20-negative B-cell precursors and hematopoietic stem cells.

Kinetics of Depletion and Recovery

The onset of B-cell depletion is rapid, occurring within 1 hour in mouse models, with CD19+ cell counts in humans almost completely depleted by week 2 after the first dose. Maximal depletion persists for extended periods, with B cells remaining extensively depleted through week 96 when infusions are administered every 24 weeks. B-cell recovery demonstrates complex kinetics varying by anatomical compartment and B-cell phenotype.

Comparative Analysis with Other Anti-CD20 Antibodies

Ocrelizumab exhibits distinct mechanistic properties compared to other anti-CD20 antibodies. While all anti-CD20 agents induce both ADCC and CDC, their relative reliance on these pathways differs substantially. Ocrelizumab and ublituximab primarily use ADCC for B-cell depletion, whereas rituximab and ofatumumab rely more heavily on CDC.

Secondary Effects on Immune Regulation

BAFF-APRIL System Modulation

Ocrelizumab treatment induces profound changes in the B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) system. The treatment persistently enhances BAFF levels while reducing the endogenous soluble receptor and decoy sTACI in both serum and CSF.

Broader Immunological Changes

B-cell depletion is accompanied by decreases in B-cell receptor and cytokine signaling pathways. At 6 months, treatment reduces plasma abundance of cytokines and cytotoxic proteins, markers of neuronal damage, and biologically active lipids including ceramides and lysophospholipids.

Synthesis

The mechanism by which ocrelizumab drives B-cell depletion involves multiple coordinated processes that vary by context, anatomical location, and B-cell phenotype. The apparent heterogeneity in depletion efficiency and recovery patterns across different compartments and studies can be reconciled through several key considerations.